ReviewInternational journal of molecular sciences2026
Vitiligo-Current Treatment Options and Future Perspectives.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Vitiligo is a chronic autoimmune disease characterized by the loss of melanocytes, resulting in the appearance of depigmented patches on the skin. The aim of the present review is to discuss current therapeutic methods and to outline promising directions for the treatment of this dermatosis. The review describes pathogenetic mechanisms, including the role of oxidative stress, immune dysregulation, and the JAK/STAT pathways, which constitute the foundation of contemporary therapeutic interventions. The efficacy and safety of topical treatments (corticosteroids, calcineurin inhibitors, JAK inhibitors), phototherapy (NB-UVB, PUVA, excimer laser), combination therapies, and surgical methods such as cellular and tissue grafts are discussed. Data indicate that the combination of phototherapy with topical agents enhances repigmentation efficacy, and JAK inhibitors represent promising drugs in targeted therapy. Particular value is attributed to preparations modulating the immune response and to melanocyte transplantation techniques, which emerge as highly effective and forward-looking treatment options for vitiligo. Nevertheless, effective management of vitiligo requires a multidirectional approach combining pharmacological, immunomodulatory, and regenerative interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.